Nuformix Share Discussion Threads

[soupdragon55] 31/1/2018 14:17

Possible Near Term Share Price Catalyst
We expect news on an out-licensing deal quite shortly, which could further validate NFX’s cocrystal technology and the progress made with this to date. In addition, we look for a boost to near and medium term income, which could allow NFX to progress further with the development of its other products.

[soupdragon55] 31/1/2018 14:10

Plus Beauforts 10p Target note.

[soupdragon55] 31/1/2018 14:03

Interview with Dr Goodman now on Vox at 17mins 55secs.

[rathean] 31/1/2018 08:17

Resistance at 4p, if we finish above could see a good few pennies added to the share price. Great RNS, opens up a huge market in addition to other formulas being licensed for recurring revenues.

[curlly] 31/1/2018 07:39

That's a good update

[soupdragon55] 31/1/2018 07:12

31 January 2018Nuformix Plc("Nuformix" or "the Company")Positive Results from NXP002 Pilot Study in Lung and Liver FibrosisNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces a positive outcome following innovative pilot studies in multiple fibrotic diseases for its NXP002 programme.Summary -- Positive indication of efficacy using cutting-edge human tissue disease models -- Demonstration that NXP002 inhibits fibrosis in functional human tissue via a dual-action, significantly addressing both inflammation and fibrosis components responsible for disease progression-- Results show a profound effect in inhibiting established human fibrotic disease, offering future benefits to a wide spectrum of patients -- Proven safety and tolerability offers significant advantages over competitor products -- Rapidly growing markets already valued in multiple billions Working in parallel with the University of Newcastle and Fibrofind and their proprietary fibrosis research models, Nuformix has completed pilot pre-clinical studies that further validate the potential for its NXP002 programme in successfully and safely treating fibrosis.Fibrotic disease is typically associated with high patient mortality, increasing prevalence and a lack of safe and effective treatments. Using cutting-edge human tissue disease models, the studies have focussed on the potential for NXP002 to halt progression in established lung and liver fibrosis. The results demonstrate that NXP002 strongly inhibits fibrosis in functional human tissue via a dual-action, which significantly addresses both the inflammation and fibrosis components responsible for fibrotic disease progression.Following success in these innovative pilot studies Nuformix has commenced additional studies to further support progress to use in patients, which will run in parallel to Nuformix's human pharmacokinetic studies for NXP002.Dr Dan Gooding, CEO, Nuformix plc, said: "Traditional pre-clinical fibrosis models offer limited utility as they don't recreate the disease in a genetically or physiologically relevant way, meaning success doesn't always translate into patients. In contrast, the studies conducted at Newcastle University and Fibrofind put the Nuformix NXP002 programme as close to patient as possible. The results show a profound effect in inhibiting established fibrotic disease, importantly at exposure levels that we know are well-tolerated in patients and levels which the team are confident can consistently be delivered using Nuformix proprietary drug forms."We can take great confidence from our pilot data, particularly in lung fibrosis, where we are able to study living human disease tissue. Our data demonstrates NXP002 is superior to recently approved treatments, whilst also providing the additional benefit of vastly increased tolerability in long-term use, which is not currently possible."These results give us great confidence in what will happen when NXP002 reaches patients and robustly support entry to patient proof-of-concept studies immediately after completion of our pharmacokinetic studies."This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

[soupdragon55] 30/1/2018 17:44

Good turn around today.

[bbmsionlypostafter] 29/1/2018 12:27

Is Aberdeenman still ramping this?

[h0me] 29/1/2018 11:50

News coming we assume

[soupdragon55] 29/1/2018 10:28

Push thru 4p should help it up to 5p+. Possible news ahead.

[soupdragon55] 26/1/2018 08:43

Good strength to start the day. Momentum should see this to 4p, then hopefully some news to back it up.

[croasdalelfc] 26/1/2018 08:40

Bowl forming on chart with daily rises on increasing volume - pity I bought too early - break even now

[modform] 26/1/2018 08:36

I had been building a position here early this week, high risk but huge potential

[soupdragon55] 26/1/2018 07:37

Test of momentum today. Strong finish yesterday with breakout, now to see if it continues the push.

[costax1654x] 25/1/2018 19:37

I think after FFI with Massive directors buys this one is one to watch as well!

[soupdragon55] 25/1/2018 19:17

So far under the radar here.Good shift in volume recently, looking like seller has moved on. Also interesting pattern that quite a few buys tend to come in a surge between 11am and 1.

[rathean] 25/1/2018 15:07

Still nudging north. Reckon NW is trying to save what's left of his portfolio? This and PURP his two best bets :)

[babbler] 19/1/2018 11:59

Ticj up coming.

[croasdalelfc] 18/1/2018 12:09

This was Leaky last time - rose from 11th to 15th was RNS issued

[croasdalelfc] 18/1/2018 10:36

Or a leak or oversold , take your pick

[rathean] 18/1/2018 10:15

16% gain on no news... RNS due soon on new licencing deal?

[rathean] 22/12/2017 11:29

Great entry point at this price, fully funded, huge scope for adding additional revenue streams from rest of World deals... the one shining light in Woodford's trust.

[croasdalelfc] 19/12/2017 20:41

From October - Early out-licensing -NPX001- enables Nuformix to self-fund future R&D (potential revenue in excess of £10m)

[croasdalelfc] 19/12/2017 20:00

Https://nuformix.com/app/uploads/2017/10/Nuformix-Investor-Summary-.pdf

[simpletonremover] 19/12/2017 18:07

Very droll.

You weren't 'correcting', you were 'adding' by using the word 'full', and then trying to correct the addition you'd made yourself. It was bordering on a soliloquy.

Timewaster.

Trot on.